Chemo/Dietary prevention of cancer: Perspectives in China

Journal of Biomedical Research

Volumn 28, Issue 6, 2014, Pages 447-455

  Yang, Chung S ^a   Fengb, Qing ^b  

^a RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Cancer chemoprevention; Dietary; Intervention

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANDROGEN; BETA CAROTENE; CARCINOGEN; CATECHIN; FENRETINIDE; FINASTERIDE; FISH OIL; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; POLYPHENOL; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; SELENIUM; TAMOXIFEN; TOCOPHEROL;

BREAST CANCER; CANCER PREVENTION; CARCINOGENESIS; CHEMOPROPHYLAXIS; CHINA; COHORT ANALYSIS; COLON ADENOMA; COLON CANCER; COLORECTAL CANCER; DIET SUPPLEMENTATION; DIET THERAPY; FRUIT; HIGH RISK POPULATION; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SOCIAL STATUS; VEGETABLE;

EID: 84929575503     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.28.20140079     Document Type: Review

References (57)

1. Yang CS. Research on esophageal cancer in China: a review. Cancer Res 1980;40:2633-44.
2. Wattenberg LW. Chemoprophylaxis of carcinogenesis: a review. Cancer Res 1966;26:1520-6.
3. Sporn MB. Approaches to prevention of epithelial cancer during the preneoplastic period. Cancer Res 1976;36:2699-702.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008;371:569-78.
5. Umar A, Dunn BK, Greenwald P. Future directions in cancer prevention. Nat rev Cancer 2012;12:835-48.
6. Dunn BK, Ryan A. Phase 3 trials of aromatase inhibitors for breast cancerprevention: following in the path of the selective estrogen receptor modulators. Ann N Y Acad Sci 2009;1155:141-61.
7. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381:1827-34.
8. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Eng J Med 2010;362:1192-202.
9. Bettuzzi S, Brausi M, Rizzi F, Castagnetti G, Peracchia G, Corti A. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006;66:1234-40.
10. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13:759-71.
11. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res (Philadelphia, Pa) 2012;5:164-78.
12. Fink SP, Yamauchi M, Nishihara R, Jung S, Kuchiba A, Wu K, et al. Aspirin and the Risk of Colorectal Cancer in Relation to the Expression of 15-Hydroxyprostaglandin Dehydrogenase (HPGD). Sci Transl Med 2014;6:233re2.
13. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial. Ann Intern Med 2013;159:77-85.
14. Huang ES, Strate LL, Ho WW, Lee SS, Chan AT. Long-term use of aspirin and the risk of gastrointestinal bleeding. Am J Med 2011;124:426-33.
15. Rothwell PM, Price JF, Fowkes FG, Zanchetti A, Roncaglioni MC, Tognoni G, et al. Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 2012;379:1602-12.
16. Algra AM, Rothwell PM. Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncol 2012;13:518-27.
17. Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006;355:873-84.
18. Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006;355:885-95.
19. Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006;355:950-2.
20. Meyskens FL, Jr., McLaren CE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res 2008;1:32-8.
21. Blot WJ, Li J-Y, Taylor PR, Guo W, Dawsey S, Wang G-Q, et al. Nutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Nat Cancer Inst 1993;85:1483-91.
22. Taylor PR, Qiao YL, Abnet CC, Dawsey SM, Yang CS, Gunter EW, et al. Prospective study of serum vitamin E levels and esophageal and gastric cancers. J Nat Cancer Inst 2003;95:1414-6.
23. Mark SD, Qiao YL, Dawsey SM, Wu YP, Katki H, Gunter EW, et al. Prospective study of serum selenium levels and incident esophageal and gastric cancers. J Nat Cancer Inst 92:1753-63.
24. Qiao YL, Dawsey SM, Kamangar F, Fan JH, Abnet CC, Sun XD, et al. Total and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian General Population Nutrition Intervention Trial. J Nat Cancer Inst 2009;101:507-18.
25. Yang H, Fang J, Jia X, Han C, Chen X, Yang CS, et al. Chemopreventive effects of early-stage and late-stage supplementation of vitamin E and selenium on esophageal carcinogenesis in rats maintained on a low vitamin E/selenium diet. Carcinogenesis 2011;32:381-8.
26. Peto R, Doll R, Buckley JD, Sporn MB. Can dietary betacarotene materially reduce human cancer rates? Nature 1981;290:201-8.
27. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330:1029-35.
28. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, et al. Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. J Nat Cancer Inst 1998;90:440-6.
29. Clark LC, Combs GF, Jr., Turnbull BW, Slate EH, Chalker DK, Chow J, et al. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. J Am Med Asso 1996;276:1957-63.
30. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Am Med Asso 2009;301:39-51.
31. Klein EA, Thompson IM, Jr., Tangen CM, Crowley JJ, Lucia MS, Goodman PJ, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Am Med Asso 2011;306:1549-56.
32. Lee IM, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, et al. Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. J Am Medl Asso 2005;294:56-65.
33. Gaziano JM, Glynn RJ, Christen WG, Kurth T, Belanger C, MacFadyen J, et al. Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial. J Am Medl Asso 2009;301:52-62.
34. Martinez ME, Jacobs ET, Baron JA, Marshall JR, Byers T. Dietary supplements and cancer prevention: balancing potential benefits against proven harms. J Nat Cancer Inst 2012;104:732-9.
35. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, et al. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003;91:608-12.
36. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, et al. Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Pros 2009;69:644-51.
37. Yang CS, Suh N, Kong AN. Does vitamin E prevent or promote cancer? Cancer Prev Res 2012;5:701-5.
38. Kim YI. Folate, colorectal carcinogenesis, and DNA methylation: lessons from animal studies. Environ Mol Mutagen 2004;44:10-25.
39. Cole BF, Baron JA, Sandler RS, Haile RW, Ahnen DJ, Bresalier RS, et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. J Am Med Asso 2007;297:2351-9.
40. Gaziano JM, Sesso HD, Christen WG, Bubes V, Smith JP, MacFadyen J, et al. Multivitamins in the prevention of cancer in men: the Physicians' Health Study II randomized controlled trial. J Am Med Asso 2012;308:1871-80.
41. Yang CS, Wang X, Lu G, Picinich SC. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009;9:429-39.
42. Yuan JM, Sun C, Butler LM. Tea and cancer prevention: epidemiological studies. Pharmacol Res 2011;64:123-35.
43. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 2010;33:1304-8.
44. Li D, Yeung SC, Hassan MM, Konopleva M, Abbruzzese JL. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009;137:482-8.
45. Wright JL, Stanford JL. Metformin use and prostate cancer in Caucasian men: results from a population-based case-control study. Cancer Causes Control 2009;20:1617-22.
46. Lee MS, Hsu CC, Wahlqvist ML, Tsai HN, Chang YH, Huang YC. Type 2 diabetes increases and metformin reduces total, colorectal, liver and pancreatic cancer incidences in Taiwanese: a representative population prospective cohort study of 800,000 individuals. BMC Cancer 2011;11:20.
47. Sadeghi N, Abbruzzese JL, Yeung SC, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res 2012;18:2905-12.
48. Singh S, Singh PP, Singh AG, Murad MH, McWilliams RR, Chari ST. Anti-diabetic medications and risk of pancreatic cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Am J Gastroenterol 2013;108:510-9,; quiz 20.
49. Yue W, Yang CS, DiPaola RS, Tan XL. Repurposing of metformin and aspirin by targeting AMPK-mTOR and inflammation for pancreatic cancer prevention and treatment. Cancer Prev Res (Phila) 2014;7:388-97.
50. Tan XL, Reid Lombardo KM, Bamlet WR, Oberg AL, Robinson DP, Anderson KE, et al. Aspirin, nonsteroidal anti-inflammatory drugs, acetaminophen, and pancreatic cancer risk: a clinic-based case-control study. Cancer Prev Res 2011;4:1835-41.
51. Muchow M, Maincent P, Muller RH. Lipid nanoparticles with a solid matrix (SLN, NLC, LDC) for oral drug delivery. Drug Dev Ind Pharm 2008;34:1394-405.
52. Lim SB, Banerjee A, Onyuksel H. Improvement of drug safety by the use of lipid-based nanocarriers. J Control Release 2012;163:34-45.
53. Grandhi BKTA, Wang J, Prabbhu S. A novel combinatorial naotechnology-based oral chemopreventive regimen demonstrates significant suppression of pancreatic cancer neoplastic lesions. Cancer Prev Res 2013:6:1015-25.
54. Battaglia L, Gallarate M. Lipid nanoparticles: state of the art, new preparation methods and challenges in drug delivery. Expert Opin Drug Deliv 2012;9:497-508.
55. Fahey JW, Talalay P, Kensler TW. Notes from the field: "green" chemoprevention as frugal medicine. Cancer Prev Res 2012;5:179-88.
56. Zhang W, Shu XO, Li H, Yang G, Cai H, Ji BT, et al. Vitamin intake and liver cancer risk: a report from two cohort studies in China. J Nat Cancer Inst 2012;104:1173-81.
57. World Cancer Reserch Fund. Food, Nutrition, physical activity, and the prevention of cancer: a global perspective 2007 http://www.dietandcancerreport.org/expert_report/report_contents/index.php